Anti-thyroid peroxidase antibody, IA-2 antibody, and fasting C-peptide levels predict beta cell failure in patients with latent autoimmune diabetes in adults (LADA)-A 5-year follow-up of the Ehime study

Diabetes Research and Clinical Practice

Volumn 80, Issue 1, 2008, Pages 114-121

  Murao, Satoshi ^a   Kondo, Shiori ^b   Ohashi, Jun ^c   Fujii, Yasuhisa ^d   Shimizu, Ikki ^d   Fujiyama, Masao ^e   Ohno, Keizo ^d   Takada, Yasuharu ^f   Nakai, Kazuaki ^g   Yamane, Yukio ^h   Osawa, Haruhiko ⁱ   Makino, Hideichi ⁱ  

^a Matsuyama Shimin Hospital   (Japan)

^b MATSUYAMA RED CROSS HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^e Fujiyama Clinic   (Japan)

^f Saijo Central Hospital   (Japan)

^g N   (Japan)

^h Juzen General Hospital   (Japan)

ⁱ EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Beta cell failure; GADAb; IA 2Ab; LADA; TPOAb

Indexed keywords

AUTOANTIBODY; C PEPTIDE; HLA ANTIGEN CLASS 2; IA 2 ANTIBODY; INSULIN; THYROID PEROXIDASE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; JAPAN; LATENT AUTOIMMUNE DIABETES IN ADULT; MALE; MATURITY ONSET DIABETES MELLITUS; PANCREAS INSUFFICIENCY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FAILURE; PANCREAS ISLET CELL FUNCTION;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; BIOLOGICAL MARKERS; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; INSULIN; INSULIN-SECRETING CELLS; IODIDE PEROXIDASE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 40849083371     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.01.024     Document Type: Article

References (38)

1. Atkinson M.A., and Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358 (2001) 221-229
2. Irvine W.J., McCallum C.J., Gray R.S., and Duncan L.J. Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet 1 (1977) 1025-1027
3. Groop L.C., Bottazzo G.F., and Doniach D. Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis. Diabetes 35 (1986) 237-241
4. Kobayashi T., Itoh T., Kosaka K., Sato K., and Tsuji K. Time course of islet cell antibodies and beta-cell function in non-insulin-dependent stage of type I diabetes. Diabetes 36 (1987) 510-517
5. Kobayashi T., Tamemoto K., Nakanishi K., Kato N., Okubo M., Kajio H., et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 16 (1993) 780-788
6. Tuomi T., Groop L.C., Zimmet P.Z., Rowley M.J., Knowles W., and Mackay I.R. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42 (1993) 359-362
7. Turner R., Stratton I., Horton V., Manley S., Zimmet P., Mackay I.R., et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350 (1997) 1288-1293
8. Tuomi T., Carlsson A., Li H., Isomaa B., Miettinen A., Nilsson A., et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48 (1999) 150-157
9. Abiru N., Takino H., Yano M., Kawasaki E., Yamasaki H., Yamaguchi Y., et al. Clinical evaluation of non-insulin-dependent diabetes mellitus patients with autoantibodies to glutamic acid decarboxylase. J. Autoimmun. 9 (1996) 683-688
10. Takeda H., Kawasaki E., Shimizu I., Konoue E., Fujiyama M., Murao S., et al. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime study). Diabetes Care 25 (2002) 995-1001
11. Takino H., Yamasaki H., Abiru N., Sera Y., Abe T., Kawasaki E., et al. Antibodies to GAD in Japanese patients classified as Type 2 diabetes at diagnosis. High titre of GAD Ab is a predictive marker for early insulin treatment-report of west Japan (Kyushu, Yamaguchi, Osaka) study for GAD Ab(+) diabetes. Diabet. Med. 19 (2002) 730-734
12. Nakanishi K., Kobayashi T., Inoko H., Tsuji K., Murase T., and Kosaka K. Residual beta-cell function and HLA-A24 in IDDM. Markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes 44 (1995) 1334-1339
13. The Diabetes Control Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann. Intern. Med. 128 (1998) 517-523
14. Gottsater A., Landin-Olsson M., Fernlund P., Lernmark A., and Sundkvist G. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 16 (1993) 902-910
15. Kasuga A., Maruyama T., Nakamoto S., Ozawa Y., Suzuki Y., and Saruta T. High-titer autoantibodies against glutamic acid decarboxylase plus autoantibodies against insulin and IA-2 predicts insulin requirement in adult diabetic patients. J. Autoimmun. 12 (1999) 131-135
16. Torn C., Landin-Olsson M., Lernmark A., Palmer J.P., Arnqvist H.J., Blohme G., et al. Prognostic factors for the course of beta cell function in autoimmune diabetes. J. Clin. Endocrinol. Metab. 85 (2000) 4619-4623
17. Borg H., Gottsater A., Landin-Olsson M., Fernlund P., and Sundkvist G. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J. Clin. Endocrinol. Metab. 86 (2001) 3032-3038
18. Niskanen L.K., Tuomi T., Karjalainen J., Groop L.C., and Uusitupa M.I. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 18 (1995) 1557-1565
19. Fourlanos S., Dotta F., Greenbaum C.J., Palmer J.P., Rolandsson O., Colman P.G., et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48 (2005) 2206-2212
20. Awata T., Kuzuya T., Matsuda A., Iwamoto Y., and Kanazawa Y. Genetic analysis of HLA class II alleles and susceptibility to type 1 (insulin-dependent) diabetes mellitus in Japanese subjects. Diabetologia 35 (1992) 419-424
21. Murao S., Makino H., Kaino Y., Konoue E., Ohashi J., Kida K., et al. Differences in the contribution of HLA-DR and -DQ haplotypes to susceptibility to adult- and childhood-onset type 1 diabetes in Japanese patients. Diabetes 53 (2004) 2684-2690
22. Matsuda A., Kamata I., Iwamoto Y., Sakamoto Y., and Kuzuya T. A comparison of serum C-peptide response to intravenous glucagon, and urine C-peptide, as indexes of insulin dependence. Diabetes Res. Clin. Pract. 1 (1985) 161-167
23. Gjessing H.J., Matzen L.E., Faber O.K., and Froland A. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia 32 (1989) 305-311
24. Kobayashi T., Maruyama T., Shimada A., Kasuga A., Kanatsuka A., Takei I., et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann. NY Acad. Sci. 958 (2002) 117-130
25. Lohmann T., Kellner K., Verlohren H.J., Krug J., Steindorf J., Scherbaum W.A., et al. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 44 (2001) 1005-1010
26. Desai M., Cull C.A., Horton V.A., Christie M.R., Bonifacio E., Lammpasona V., et al. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia 50 (2007) 2052-2060
27. Bottazzo G.F., Bosi E., Cull C.A., Bonifacio E., Locatelli M., Zimmet P., et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 48 (2005) 703-708
28. Kawasaki E., Takino H., Yano M., Uotani S., Matsumoto K., Takao Y., et al. Autoantibodies to glutamic acid decarboxylase in patients with IDDM and autoimmune thyroid disease. Diabetes 43 (1994) 80-86
29. Dayan C.M., and Daniels G.H. Chronic autoimmune thyroiditis. N. Engl. J. Med. 335 (1996) 99-107
30. Barker J.M., Yu J., Yu L., Wang J., Miao D., Bao F., et al. Autoantibody "subspecificity" in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care 28 (2005) 850-855
31. Hamaguchi K., Kimura A., Kusuda Y., Yamashita T., Yasunami M., Takahasi M., et al. Clinical and genetic characteristics of GAD-antibody positive patients initially diagnosed as having type 2 diabetes. Diabetes Res. Clin. Pract. 66 (2004) 163-171
32. Gambelunghe G., Forini F., Laureti S., Murdolo G., Toraldo G., Santeusanio F., et al. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin. Endocrinol. (Oxf.) 52 (2000) 565-573
33. Barker J.M. Clinical review: type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J. Clin. Endocrinol. Metab. 91 (2006) 1210-1217
34. Tomer Y., and Davies T.F. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr. Rev. 24 (2003) 694-717
35. Horton V., Stratton I., Bottazzo G.F., Shattock M., Mackay I., Zimmet P., et al. Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). Diabetologia 42 (1999) 608-616
36. Gambelunghe G., Ghaderi M., Tortoioli C., Falorni A., Santeusanio F., Brunetti P., et al. Two distinct MICA gene markers discriminate major autoimmune diabetes types. J. Clin. Endocrinol. Metab. 86 (2001) 3754-3760
37. Vatay A., Rajczy K., Pozsonyi E., Hosszufalusi N., Prohaszka Z., Fust G., et al. Differences in the genetic background of latent autoimmune diabetes in adults (LADA) and type 1 diabetes mellitus. Immunol. Lett. 84 (2002) 109-115
38. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423 (2003) 506-511